Answers are grounded in this paper and cite their sources.
Insulin resistance (IR) is a key pathophysiologic component of the polycystic ovary syndrome (PCOS) and an important cardiovascular risk factor. Endothelial dysfunction occurs early in the development of cardiovascular disease and is also an important component of PCOS. Measures of endothelial function that are associated with increased cardiovascular risk include reduced flow-mediated dilation and increased levels of circulating plasminogen activator inhibitor-1 (PAI-1), and asymmetric dimethylarginine (ADMA). All 3 measures are predictive for cardiovascular disease as are increased levels of the inflammatory marker, high-sensitivity C-reactive protein (hsCRP). The oral contraceptive pill (OCP) and metformin are commonly used for treatment in women with PCOS in addition to lifestyle intervention, which is the first-line treatment. Metformin improves reproductive features and IR in PCOS but there are scant data on its effects on endothelial function and available data is contradictory. Although OCP also improves reproductive features in PCOS, it has adverse effects on IR as well as on other cardiovascular risk factors and appears to improve low-density lipoprotein cholesterol (LDL-C) and ADMA despite increased IR. This randomized controlled open-label clinical study compared the effect of metformin and the OCP on cardio-metabolic features of PCOS. The aim of the study was to evaluate the interaction between insulin resistance and endothelial function and investigate the optimal treatment strategy addressing cardiovascular risk in PCOS. The study subjects were overweight age- and body mass index–matched women with PCOS. A total of 66 patients were randomized to receive metformin (1 gm twice daily, n = 36) or OCP (35 mg ethinyl E2–2 mg cytoproterone acetate, n = 30) for 6 months. Of these, 56 completed the study (metformin n = 30 and OCP n = 26). The primary outcome measures were fasting glucose levels and oral glucose tolerance test (OGTT) levels of glucose and insulin, flow-mediated dilation, and levels of ADMA, PAI-1, and hsCRP, lipids (LDL-C and high-density lipoprotein cholesterol [HDL-C]), triglycerides, and hyperandrogenism. There were differential effects on the primary outcome measures for metformin and OCP. Metformin was associated with decreased levels of both fasting and OGTT insulin, HDL-C, and hs-CRP. The OCP was associated with increased levels of both glucose and insulin OGTT, hsCRP, triglycerides, and sex-hormone binding globulin and with decreased levels of LDL-C and testosterone. There were increases in flow-mediated dilation with metformin (−2.2% ± 4.8%) but not with the OCP, whereas equivalent decreases were found in ADMA with both OCP and metformin (−0.3 ± 0.1 and −0.1 ± 0.1 mmol/L, respectively). The OCP was associated with greater decreases in PAI-1 than metformin (−1.8 ± 1.6 vs. −0.7 ± 1.7 U/mL). These findings demonstrate differential effects of metformin and the OCP on IR, endothelial function, hsCRF, and other cardiovascular risk factors in overweight women with PCOS.
No takes yet. Share an insight, caveat, or question.
Teede et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: